TNBC does not express hormone receptors and Her-2, cannot benefit from endocrine therapy and Her-2 targeted therapy, and their pathological characteristics, treatment and prognosis are very different from those of other types of breast cancer, which has attracted much attention (5). This evidence concerns the gene NR4A1 and breast carcinoma.